Skip to main content

Spondylitis, Ankylosing

17
Pipeline Programs
11
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
9
8
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1794%
Small Molecule
16%
+ 9 programs with unclassified modality

Competitive Landscape

10 companies ranked by most advanced pipeline stage

MSD
MSDIreland - Ballydine
8 programs
2
4
InfliximabPhase 4Monoclonal Antibody
PDUSPhase 4
RemicadePhase 4
RemicadePhase 4
GolimumabPhase 3Monoclonal Antibody
+3 more programs
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
8 programs
2
4
InfliximabPhase 4Monoclonal Antibody
PDUSPhase 4
RemicadePhase 4
RemicadePhase 4
GolimumabPhase 3Monoclonal Antibody
+3 more programs
Sandoz
SandozAustria - Kundl
3 programs
3
SecukinumabPhase 3Monoclonal Antibody1 trial
SecukinumabPhase 3Monoclonal Antibody1 trial
SecukinumabPhase 3Monoclonal Antibody1 trial
Active Trials
NCT02008916Completed226Est. Dec 2017
NCT01863732Completed274Est. Mar 2018
NCT02159053Completed350Est. Jan 2018
Pfizer
PfizerNEW YORK, NY
1 program
1
CelecoxibPhase 3Small Molecule1 trial
Active Trials
NCT00648141Completed458Est. Jan 2005
Prevail Therapeutics
1 program
1
IxekizumabPhase 3Monoclonal Antibody
Roche
RocheSTAVANGER NORWAY, Norway
2 programs
TocilizumabPHASE_3Monoclonal Antibody1 trial
tocilizumabPHASE_3Monoclonal Antibody1 trial
Active Trials
NCT01209689Terminated113Est. Dec 2011
NCT01209702Terminated306Est. Dec 2011
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
A Multicenter Registry of Adalimumab in Chinese Adult Patients With Active Ankylosing SpondylitisN/A1 trial
Active Trials
NCT01901627Unknown400Est. Jun 2015
Merck & Co.
Merck & Co.RAHWAY, NJ
1 program
InfliximabN/AMonoclonal Antibody1 trial
Active Trials
NCT00725543Completed358Est. Jun 2010
Integrated Biosciences
Integrated BiosciencesCA - San Carlos
1 program
tapering or discontinuation of etanerceptN/A1 trial
Active Trials
NCT03880968Completed311Est. Sep 2014
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
1 program
Meloxicam suppositoryPHASE_31 trial
Active Trials
NCT02183168Completed192

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SandozSecukinumab
SandozSecukinumab
SandozSecukinumab
RocheTocilizumab
Rochetocilizumab
PfizerCelecoxib
Boehringer IngelheimMeloxicam suppository
UNION therapeuticsA Multicenter Registry of Adalimumab in Chinese Adult Patients With Active Ankylosing Spondylitis
Integrated Biosciencestapering or discontinuation of etanercept
Merck & Co.Infliximab

Clinical Trials (10)

Total enrollment: 2,988 patients across 10 trials

NCT02159053SandozSecukinumab

16-week Efficacy and 2-year Safety, Tolerability and Efficacy of Secukinumab in Participants With Active Ankylosing Spondylitis

Start: May 2015Est. completion: Jan 2018350 patients
Phase 3Completed
NCT02008916SandozSecukinumab

16-week Efficacy and 3-year Safety, Tolerability and Efficacy of Secukinumab in Active Ankylosing Spondylitis Patients

Start: Jan 2014Est. completion: Dec 2017226 patients
Phase 3Completed
NCT01863732SandozSecukinumab

Extension in AS: Sustainability of Benefits, Safety and Tolerability

Start: Nov 2013Est. completion: Mar 2018274 patients
Phase 3Completed
NCT01209689RocheTocilizumab

A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy

Start: Oct 2010Est. completion: Dec 2011113 patients
Phase 3Terminated
NCT01209702Rochetocilizumab

A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs

Start: Sep 2010Est. completion: Dec 2011306 patients
Phase 3Terminated
NCT00648141PfizerCelecoxib

Safety and Efficacy of Celecoxib Versus Diclofenac in the Treatment of Ankylosing Spondylitis

Start: Jan 2003Est. completion: Jan 2005458 patients
Phase 3Completed
NCT02183168Boehringer IngelheimMeloxicam suppository

Evaluation of Efficacy and Safety of Meloxicam Suppository (15mg Daily) and Tablet (15 mg Daily) Compared to Indomethacin Suppository (50 mg Daily) in Patients With Ankylosing Spondylitis

Start: Jul 2001192 patients
Phase 3Completed
NCT01901627UNION therapeuticsA Multicenter Registry of Adalimumab in Chinese Adult Patients With Active Ankylosing Spondylitis

A Multicenter Registry of Adalimumab in Chinese Adult Patients With Active Ankylosing Spondylitis

Start: Apr 2013Est. completion: Jun 2015400 patients
N/AUnknown
NCT03880968Integrated Biosciencestapering or discontinuation of etanercept

Treat-to-Target Strategy With Etanercept for Ankylosing Spondylitis

Start: Mar 2012Est. completion: Sep 2014311 patients
N/ACompleted
NCT00725543Merck & Co.Infliximab

Investigation of 9 Consecutive Remicade Infusions in Ankylosing Spondylitis in Austria (Study P04044)(COMPLETED)

Start: Jun 2004Est. completion: Jun 2010358 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

9 late-stage (Phase 3) programs, potential near-term approvals
Monoclonal Antibody is the dominant modality (94% of programs)
11 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.